Pomegranate + polygonum cuspidatum + trifolium pratense extract
Pomegranate + polygonum cuspidatum + trifolium pratense extract has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Feb 23, 2026: “Precision health targeting TMAO in postmenopausal women: polyphenol effects modulated by urolithin A and equol metabotypes in a randomised, placebo-controlled crossover trial”.
1 paper studies it2 findingsUpdated
“the intervention reduced urinary TMAO and DMA versus baseline and placebo”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Agencia Estatal de Investigación and 5 more
- Human trial1
What did studies of Pomegranate + polygonum cuspidatum + trifolium pratense extract find?
2Studies of Pomegranate + polygonum cuspidatum + trifolium pratense extract measured 2 outcomes; the most studied are dimethylamine (1 study) and TMAO (1).
Dimethylamine
downin humans1
1 study
Dimethylamine
downin humans1
Pomegranate + polygonum cuspidatum + trifolium pratense extract decreases dimethylamine in humans.
“intervention reduced urinary TMAO and DMA versus baseline and placebo”
Human trialpostmenopausal women
Food & function
TMAO
downin humans1
1 study
TMAO
downin humans1
Pomegranate + polygonum cuspidatum + trifolium pratense extract decreases TMAO in humans.
“the intervention reduced urinary TMAO and DMA versus baseline and placebo”
Human trialpostmenopausal women
Food & function